161 related articles for article (PubMed ID: 9657662)
1. Tumour-infiltrating lymphocytes in non-small cell lung cancer are activated T lymphocytes.
Kuo SH; Chang DB; Lee YC; Lee YT; Luh KT
Respirology; 1998 Mar; 3(1):55-9. PubMed ID: 9657662
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood and tumor infiltrating lymphocytes in non-small cell lung cancer: analysis at the population and clonal level.
Viale M; Ferrini S; Serrano S; Serrano D; Ardizzoni A; Nicolin A
Tumori; 1990 Oct; 76(5):488-94. PubMed ID: 2175060
[TBL] [Abstract][Full Text] [Related]
3. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
4. The Characteristics of Naive-like T Cells in Tumor-infiltrating Lymphocytes From Human Lung Cancer.
Sheng SY; Gu Y; Lu CG; Tang YY; Zou JY; Zhang YQ; Wang RF; Hong H
J Immunother; 2017 Jan; 40(1):1-10. PubMed ID: 27828929
[TBL] [Abstract][Full Text] [Related]
5. Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma.
Kopecký O; Lukesová S; Vroblová V; Vokurková D; Morávek P; Safránek H; Hlávková D; Soucek P
Acta Medica (Hradec Kralove); 2007; 50(3):207-12. PubMed ID: 18254275
[TBL] [Abstract][Full Text] [Related]
6. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.
Grimm M; Feyen O; Hofmann H; Teriete P; Biegner T; Munz A; Reinert S
Tumour Biol; 2016 Mar; 37(3):3807-16. PubMed ID: 26474587
[TBL] [Abstract][Full Text] [Related]
8. [Monitoring of anti-tumour cell-mediated response in patients with renal cell carcinoma, disturbance of T cell proliferation].
Lukesová S; Vroblová V; Hlávková D; Kopecký O; Vokurková D; Morávek P; Safránek H; Soucek P
Vnitr Lek; 2008 Feb; 54(2):139-45. PubMed ID: 23687704
[TBL] [Abstract][Full Text] [Related]
9. Lung tissue and tumour-infiltrating T lymphocytes in patients with non-small cell lung carcinoma and chronic obstructive pulmonary disease (COPD): moderate/severe versus mild stage of COPD.
Marc MM; Korosec P; Kern I; Sok M; Ihan A; Kosnik M
Scand J Immunol; 2007 Dec; 66(6):694-702. PubMed ID: 17949407
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC class I and II expression in breast cancer patients.
Whitford P; George WD; Campbell AM
Cancer Lett; 1992 Jan; 61(2):157-64. PubMed ID: 1730139
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases.
Yoong KF; Adams DH
Br J Cancer; 1998 Apr; 77(7):1072-81. PubMed ID: 9569042
[TBL] [Abstract][Full Text] [Related]
12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
13. [Up-regulation of TIM-3 on CD4+ tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer].
Ji P; Chen D; Bian J; Xia R; Song X; Wen W; Zhang X; Zhu Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):808-11. PubMed ID: 26062425
[TBL] [Abstract][Full Text] [Related]
14. Antigen-Presenting Intratumoral B Cells Affect CD4
Bruno TC; Ebner PJ; Moore BL; Squalls OG; Waugh KA; Eruslanov EB; Singhal S; Mitchell JD; Franklin WA; Merrick DT; McCarter MD; Palmer BE; Kern JA; Slansky JE
Cancer Immunol Res; 2017 Oct; 5(10):898-907. PubMed ID: 28848053
[TBL] [Abstract][Full Text] [Related]
15. Morphological and functional characteristics of tumor-infiltrating lymphocytes from human colorectal cancers after stimulation with rIL-2.
Keller H; Wimmenauer S; Rahner S; Reimer P; von Kleist S; Farthmann EH
Eur Surg Res; 1995; 27(4):258-68. PubMed ID: 7649213
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of infiltrating lymphocytes in choroidal melanoma].
Ohta K; Norose K; Ishii K
Nippon Ganka Gakkai Zasshi; 1995 Nov; 99(11):1277-82. PubMed ID: 8533659
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
18. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
19. Effects of Glycogen Synthase Kinase-3β Inhibitor TWS119 on Proliferation and Cytokine Production of TILs From Human Lung Cancer.
Tang YY; Sheng SY; Lu CG; Zhang YQ; Zou JY; Lei YY; Gu Y; Hong H
J Immunother; 2018 Sep; 41(7):319-328. PubMed ID: 29877972
[TBL] [Abstract][Full Text] [Related]
20. Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?
Kilvaer TK; Paulsen EE; Andersen S; Rakaee M; Bremnes RM; Busund LR; Donnem T
Carcinogenesis; 2020 Dec; 41(12):1671-1681. PubMed ID: 33035322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]